INTREPID POTASH INC (IPI)       26.0773  +0.03 (+0.1%)

26.0773  +0.03 (+0.1%)

US46121Y2019 - Common Stock


Fundamental Rating

7

We assign a fundamental rating of 7 out of 10 to IPI. IPI was compared to 123 industry peers in the Chemicals industry. IPI scores excellent points on both the profitability and health parts. This is a solid base for a good stock. A decent growth rate in combination with a cheap valuation! Better keep an eye on IPI. This could make IPI a good candidate for value investing.




Profitability

Profitability Rating

7

IPI has a Return On Assets of 9.09%. This is better than the industry average of 7.57%.
IPI's Profit Margin of 21.39% is amongst the best returns of the industry. IPI outperforms 86% of its industry peers. The industry average Profit Margin is 8.83%.

The Piotroski-F score of IPI is 8.00. This is a very strong score and indicates great health and profitability for IPI.
IPI's Return On Equity of 10.10% is worse than the rest of the industry. The industry average Return On Equity is 19.27%. 84% of the industry peers have a better Return On Equity.
VS Industry

ROA (9.09%) VS Industry: 61% outperformed.

0.23
624.60

ROE (10.1%) VS Industry: 16% outperformed.

0.26
237.19

Profit Margin (21.39%) VS Industry: 86% outperformed.

0.51
45.08

Valuation

Valuation Rating

10

With a Price/Earnings Ratio of 4.39, the valuation of IPI can be described as very cheap.
Compared to an average industry Price/Earning Ratio of 11.66, IPI is valued rather cheaply. On top of this IPI is cheaper than 87% of the companies listed in the same industry.
With a Forward Price/Earnings Ratio of 7.21, the valuation of IPI can be described as cheap.
IPI's low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

When comparing the current price to the book value of IPI, it is valued rather cheaply. It is trading at 0.47 times its book value.
Compared to an average industry price book ratio of 1.82, IPI is valued rather cheaply. On top of this, IPI is cheaper than 91% of the companies listed in the same industry.
When comparing the Enterprise Value to EBITDA ratio of IPI to the average industry ratio of 8.98, IPI is valued rather cheaply. IPI is also cheaper than 92% of the companies listed in the same industry.
VS Industry

Price/Earnings (4.39) VS Industry: 87% outperformed.

178.57
1.99

Price/Book (0.47) VS Industry: 91% outperformed.

764.36
0.02

Enterprise Value/ EBITDA (2.23) VS Industry: 92% outperformed.

13,692.96
0.15

Growth

Growth Rating

4

The Earnings Per Share has grown by an impressive 212.63% over the past year.
The Earnings Per Share has been growing by 75.44% on average over the past 5 years. This is a very strong growth
Looking at the last year, IPI shows a very strong growth in Revenue. The Revenue has grown by 24.85%.
The Revenue has been growing by 13.67% on average over the past 5 years. This is quite good.

Based on estimates for the next 5 years, IPI will show a very negative growth in Earnings Per Share. The EPS will decrease by -49.44% on average per year.
The EPS growth is decreasing: in the next 5 years the growth will be less than in the last years.
IPI is expected to show a very negative growth in Revenue. In the coming 5 years, the Revenue will decrease by -10.76% yearly.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A 75.44% 212.63% -39.13% -49.44% N/A N/A
Revenue13.67% 15.32% 24.85% -4.87% -10.76% N/A N/A

Health

Health Rating

8

A Current Ratio of 3.51 indicates that IPI has no problem at all paying its short term obligations.
When comparing the Current Ratio to an average industry Current Ratio of 2.02, IPI is better placed than the average industry peer to meet its short term obligations.
With a Debt to Equity ratio of 0.00, IPI is one of the better performing companies in its industry. It outperforms 88% of its industry peers.
An Altman-Z score of 3.74 indicates that IPI is not in any danger for bankruptcy at the moment.

IPI is in better financial health than average in its industry. Its Altman-Z score is much better than the industry average of 2.50.
The Piotroski-F score of IPI is 8.00. This is a very strong score and indicates great health and profitability for IPI.
A Quick Ratio of 1.16 indicates that IPI should not have too much problems paying its short term obligations.
The Quick Ratio is in line with the industry averages, which is at 1.32.
VS Industry

Debt/Equity (0) VS Industry: 88% outperformed.

53.61
0.00

Quick Ratio (1.16) VS Industry: 43% outperformed.

0.01
65.94

Current Ratio (3.51) VS Industry: 77% outperformed.

0.01
65.94

Altman-Z (3.74) VS Industry: 75% outperformed.

-529.46
146.70

Dividend

Dividend Rating

0

No dividends for IPI!.

INTREPID POTASH INC26.0773

NYSE:IPI (3/20/2023, 2:45:21 PM)+0.03 (+0.1%)

Chartmill FA Rating
GICS Sector Materials
GICS IndustryGroup Materials
GICS Industry Chemicals
Earnings (Last) 03-06 2023-03-06/amc Earnings (Next) 05-01 2023-05-01/amc
Inst Owners 50.97% Inst Owner Change -12.01%
Ins Owners 14.73% Ins Owner Change -0.58%
Market Cap 338.29M Analysts 44
Price Target 35.19 (34.94%)

Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y) N/A DP 0%
Div Incr Years N/A Div Non Decr Years N/A
Ex-Date N/A

Surprises & Revisions
EPS beat(2) N/A Avg EPS beat(2) -28.48%
Min EPS beat(2) -44.7% Max EPS beat(2) -12.27%
EPS beat(4) 1 Avg EPS beat(4) -12.12%
Min EPS beat(4) -44.7% Max EPS beat(4) 17.8%
Revenue beat(2) 1 Avg Revenue beat(2) 11.03%
Min Revenue beat(2) -9.18% Max Revenue beat(2) 31.25%
Revenue beat(4) 3 Avg Revenue beat(4) 9.59%
Min Revenue beat(4) -9.18% Max Revenue beat(4) 31.25%
PT rev (1m) 0% PT rev (3m) -11.54%
EPS NQ rev (1m) 0% EPS NQ rev (3m) -42.62%
EPS NY rev (1m) -25.16% EPS NY rev (3m) -25.16%
Revenue NQ rev (1m) 0% Revenue NQ rev (3m) -13.79%
Revenue NY rev (1m) -3.37% Revenue NY rev (3m) -3.37%

Valuation
Industry RankSector Rank
PE 4.39
Fwd PE 7.21
P/S 1
P/FCF 16.81
P/OCF 3.81
P/B 0.47
P/tB 0.49
EV/EBITDA 2.23
EPS(TTM) 5.94 EY 22.78%
EPS(NY) 3.62 Fwd EY 13.87%
FCF(TTM) 1.55 FCFY 5.95%
OCF(TTM) 6.85 OCFY 26.26%
SpS 26.02 BVpS 55.12
TBVpS 53.15 PEG (NY) N/A
PEG (5Y) N/A

Profitability
Industry RankSector Rank
ROA 9.09%
ROE 10.1%
ROIC 10.33%
ROICexc 10.68%
ROICexgc 11.08%
OM 30.49%
PM 21.39%
GM 41.89%
ROICexgc(3y) N/A ROICexcg growth 3Y 60.38%
ROICexcg growth 5Y N/A ROICexc(3y) N/A
ROICexc growth 3Y 60.58% ROICexc growth 5Y N/A
OM growth 3Y 58.35% OM growth 5Y N/A
PM growth 3Y 51.28% PM growth 5Y N/A
GM growth 3Y 28.45% GM growth 5Y 44.33%
F-Score 8 Asset Turnover 0.43

Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 196.09%
Profit Quality 27.87%
Current Ratio 3.51
Quick Ratio 1.16
Altman-Z 3.74
F-Score 8 WACC 8.91%
ROIC/WACC 1.24 Cap/Depr(3y) 102.08%
Cap/Depr(5y) 118.8% Profit Quality(3y) N/A
Profit Quality(5y) N/A

Growth
EPS 1Y 212.63% EPS 3Y 75.44%
EPS 5Y N/A EPS growth Q2Q 38.33%
EPS Next Y -39.13% EPS Next 2Y -49.44%
EPS Next 3Y N/A EPS Next 5Y N/A
Revenue growth 1Y 24.85% Revenue growth 3Y 15.32%
Revenue growth 5Y 13.67% Revenue growth Q2Q -7.17%
Revenue Next Year -4.87% Revenue Next 2Y -10.76%
Revenue Next 3Y N/A Revenue Next 5Y N/A
EBIT growth 1Y 245.8% EBIT growth 3Y 82.61%
EBIT growth 5Y N/A EBIT Next Year -6.57%
EBIT Next 3Y N/A EBIT Next 5Y N/A
FCF growth 1Y -66.05% FCF growth 3Y N/A
FCF growth 5Y 44.45% OCF growth 1Y 12.34%
OCF growth 3Y 21.6% OCF growth 5Y 39.69%

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA